Sector: Health Care
Director information for ADMA BIOLOGICS INC (data for year 2026)
| Name | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| Adam S. Grossman | Director | 49 | ["Over 30 years of experience in the blood and plasma industry","Co-founder of the Company","Former President and Chief Operating Officer of the Company","Executive Vice President of National Hospital Specialties and GenesisBPS","Experience in launching new products and managing sales forces","Experience in managing clinical trials and business development transactions","Worked at MedImmune, Inc. on marketing teams for RSV and CMV immunoglobulins","Launched new products at the American Red Cross"] | ["North America Board of Directors of the Plasma Protein Therapeutics Association"] | 2026 |
| Alison C. Finger | Chief Operating Officer | 62 | ["Over 30 years of biotech and pharmaceutical leadership experience","Commercialized products in the US, EU, Asia, and globally","Chief Commercial Officer at bluebird bio, Inc.","Roles at Bristol-Myers Squibb Company with increasing responsibility","Managed global P&Ls","Chair of the Alliance for Regenerative Medicine Gene Therapy Section"] | ["Governance and Nominations Committee","Compensation Committee"] | 2026 |
| Eduardo Rene Salas | Director | 64 | ["Extensive experience as a financial executive","Experience on the audit committee of Intra-Cellular Therapies, Inc.","Lead independent director and audit committee chair of Embody, Inc.","Chief Financial Officer of Wellstat Therapeutics, LLC","Senior client serving audit partner of Ernst & Young LLP"] | ["Audit Committee"] | 2026 |
| Jerrold B. Grossman D.P.S. | Vice Chairman of the Board | 78 | ["over 45 years of experience in the blood and plasma industry","Chief Executive Officer of ADMA from 2007 to October 2011","founder and Chief Executive Officer of Technomed, Inc. since 1980","founder and President of GenesisBPS from 1990 to September 2025","held positions at New York Blood Center and Immuno-U.S., Inc.","Chairman of the Board of Bergen Community Blood Services","member of the New Jersey Blood Bank Task Force","founder and former director of Pascack Bancorp, Inc.","provided consulting services to government agencies and international organizations","B.A. in Economics and Finance from Fairleigh Dickinson University","M.B.A. from Fairleigh Dickinson University","D.P.S. in Business Management from Pace University"] | [] | 2026 |
| Lawrence P. Guiheen | Chairman of the Board | 75 | ["over 35 years of experience in the healthcare industry","Executive Vice President of Wellstat Management","Chief Executive Officer of Wellmond Therapeutics","Chief Commercial Officer of Kedrion Biopharma, Inc.","principal of Guiheen and Associates","over 30 years with Baxter Healthcare Corporation","past Chairman of the Global Board of Directors for the PPTA","Bachelor of Arts degree in Business Administration from Rutgers University"] | ["Governance and Nominations Committee","Audit Committee","Compensation Committee"] | 2026 |
| Steven A. Elms | Chairman of the Board | 62 | ["Managing Partner at Aisling Capital","Principal in the Life Sciences Investment Banking Group of Hambrecht & Quist","experience in financing and merger and acquisition transactions","healthcare sector experience","B.A. in Human Biology from Stanford University","M.B.A. from Kellogg Graduate School of Management at Northwestern University"] | ["Governance and Nominations Committee"] | 2026 |
| Young T. Kwon, PhD | Chairman of the Compensation Committee and the Audit Committee | 54 | ["Chief Executive Officer at Alchemab Therapeutics","Senior executive at Momenta Pharmaceuticals","Chief Financial and Business Officer at Momenta","Business development professional at Biogen","Experience in venture capital at Advanced Technology Ventures","B.S. in Biology from MIT","Ph.D. in Biological Chemistry and Molecular Pharmacology from Harvard University"] | ["Compensation Committee","Audit Committee"] | 2026 |
